Cambrex Corp., a manufacturer of small molecule APIs and finished dosage forms, is investing approximately $3 million to increase the capacity at one of its cGMP manufacturing facilities in Milan, Italy. The investment will include the installation of a new 12,000 liter reactor, as well as reconfiguration of the layout to allow for the replacement of existing centrifuges with new, more efficient equipment.   The 14,500-sq.-ft. facility manufactures intermediates and APIs under GMP conditions, ...